Monocle is in Munich with the latest on the “terror attack” as the Bavarian capital kicks off its high-stakes security ...

Robert F. Kennedy Jr, a vaccine critic who has pledged to tackle chronic disease, was confirmed by the U.S. Senate as Health ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

GN Store Nord A/S was the biggest leader among large stocks during the session, rising 8.4%, and BioGaia AB Series B rose 6.2%. Hemnet Group AB rounded out the top three leaders on Tuesday, with ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines.

COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an ...

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We ...